EXPERIENCE AND PROSPECTS FOR THE USE OF OFF-LABEL DRUGS IN ONCOLOGY
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-1.15583Keywords:
antitumor drugs, off-label useAbstract
According to the World Health Organization, half of all drugs available on the global pharmaceutical market are sometimes used for indications that are not included in the instruction for use. This method of therapy has the term “off-label use” which means the use “out of instruction”. Today, off-label drugs are also prescribed for cancer treatment. For example, a drug developed to treat one type of tumor can sometimes be used to treat other types of cancer. The treatment of certain types of pain with tricyclic antidepressants is also an example of the off-label drugs used in oncology. An example of an off-label prescription is anxiolytic medicine lorazepam, which can be used off-label as an antiemetic in cancer patients. Low doses of naltrexone are applied to treat cancer and autoimmune diseases. A retrospective analysis of modern oncotherapy indicates that oncologists often use off-label drugs in combination therapy, especially in the treatment of patients with concomitant diseases, in case of progressive development of the tumor, or to reduce the toxicity and cost of treatment components. American oncologists are of the opinion that if all the drugs prescribed by the International Recommendations failed in the treatment of cancer, doctors can prescribe off-label medications, but only if their effectiveness and safety are clearly established. The problem of the off-label use of drugs in oncology has not yet been studied in detail, however, this direction has certain promising prospects.
References
Dal Pan GJ. WHO Drug Information: Monitoring the safety of off label medicine use. WHO Drug Information 2009; 23: 21–2.
Stafford RS. Regulating off label drug use: rethinking the role of the FDA. N Engl J Med 2008; 358: 1427–9.
Khamar B. Оff label use of medicines: Medical research and medical practice. Indian J Ophthalmol 2007; 55: 411–2.
Martsevich SYu, Navsardian AR, Komkova NA. Off-label prescription of medicinal products. Possible causes and consequences. The legal regulation in Russian Federation. Rational Pharmacother Cardiol 2017; 13: 667–73 (in Russian).
Rakeev P, Drogovoz SM. Off-label use of drugs in psychiatry. In Topical issues of new drugs development: Abstracts of XXIV international scientific and practical conference of young scientists and student, April 20, 2017. Kh, 2017; 2: 164.
Levêque D. Off label use of anticancer drugs. Lancet Oncol 2008; 9: 1102–7.
Lukianchuk JO, Drogovoz SM. Side effects of off label drugs. Topical issues of new drugs development: Abstracts of XXV International Scientific and Practical Conference of Young Scientists and Student, Kharkiv, April 18–20, Kh, 2018; 267.
Pfister DG. Off label use of oncology drugs: the need for more data and then some. J Clin Oncol 2012; 30: 1–3.
Sox HC. Evaluating off-label uses of anticancer drugs: time for a change. Ann Intern Med 2009; 150: 353–4.
Drogovoz SM, Matveeva ЕV, Lukianchuk YuA. Factors contributing to side effects of drugs. Pharmacol Toxical 2018; 2: 92–6 (in Russian).
Stephens K, Gurenlian J. Ethical and legal considerations of off label drug use [Electronic resource]. 2018. Access mode: http://decisionsindentistry.com/article/ethical–and–legal–considerations–of–off–label–drug–use/.
Jennifer К. Рhаrmасеutiсаl Regulation and Offlabel Uses [Electronic resource]. National Institute on Aging research 2016; 1–14. Access mode: http://www.nber.org/aging/valmed/WhitePaper-Kao9.2016.pdf.
Tabarrok AT. Assessing the FDA via the anomaly of off label drug. Independent Review 2000; 5, 1: 25–53.
Fairbairn D, Izzard C and Holtorf M. Promotion and use of off label pharmaceuticals in Europe, the US and China [Electronic resource]. Financier Worldwide Magazine 2011. Access mode: http://www.cliffordchance.com.
American Society of Clinical Oncology (2006) Reimbursement for cancer treatment: coverage of off label drug indications. J Clin Oncol 2006; 24, 19: 3206–8.
Zaporozhan VN, Bugaitsov SG, Stepula VV, Storozhenko SА. Experience of using herceptin in treatment of advanced forms of HER2-positive breast cancer. Onkologiya 2010; 12: 147–9 (in Russian).
ESMO 2018: Carboplatin and paclitaxel may become new standard of treatment of cancer of anal canal. InterAACT Study. Access mode: htts://rosoncoweb.ru/news/oncology/2018/11/06-4.
Ponomariova OV. International experience of paclitaxel use in the treatment of patients with early breast cancer. Onkologiya 2011; 13: 234–8.
FDA News Release. FDA Commissioner announces Avastin decision: Drug not shown to bе safe and effective in breast саnсеr patients. 2011. [Electronic resource]. Access mode: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280536.htm.
Rückeshäuser P. Off label use: the legal problems of drug application beyond the licensed use. Hamburg 2011; 1–386.
Schelling P. Die rechtlichen Aspektebeim “Off–Label–Use” [Electronic resource]. Snternist 2008; 3: 322–7. Access mode: http://www.bdi.de.
Poole SG, Dooley MJ. Off label prescribing in oncology. Support Care Cancer 2004; 12: 302–5.
Casali PG, Executive Committee of ESMO. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol 2007; 18: 1923–5.
Ballard CDJ, Peterson GM, Thompson AJ, Beggs SA. Off-1аbе1 use of medicines in pediatric inpatients at an Australian teaching hospital. J Paediatr Child Health 2012; 49: 544–8.
Guide В, Nocco L. The debate concerning the off 1аbе1 prescriptions of drugs: а comparison between Italian US law. Opinio Juris Compar 2011; 1: 45.
Delpeuch A, Leveque D, Rob L, Bergerat JP. Off-label use of oxaliplatin in patients with metastatic breast cancer. Anticancer Res 2011; 31: 1765–7.
Gillick MR. Controlling off label medication use. Ann Intern Med 2009; 150: 344–7.
Emmerich J, Dumarcet N, Lorence A. France’s new framework for regulating off label drug use. N Engl J Med 2012; 367: 1279–81.
Drogou F, Netboute A, Giai J, et al. Off-label drug prescriptions in French general practice: A crosse-sectional study. BMj 2019; 9: 4. Access mode: https://bmjopen.bmj.com/content/9/4/e026076.long.
Skanland SS, Cieślar-Pobuda A. Off-label uses of drugs for depression. Eur J Pharmacol 2019; 865: 1–11.
Lukianchuk JО, Drogovoz SM. Off label use of drugs in оnсоlоgу. Topical issues of new drugs development: Abstracts of XXIV International Scientific and Practical Conference of Young Scientists and Student, Kharkiv, April 20, Kh, 2017; 158.
Kimland Е, Odlind V. Оff label drug use in pediatric patients. Clin Рhаrmасоl Therap 2012; 91: 796–801.
Frattarelli DA, Galinkin JL, Green TP, et al. Off-label use of drugs in chidren. Pediatrics 2014; 133: 563–7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
